PaulSamuelGaynonMD

Pediatric Hematology & Oncology • Los Angeles, CA

Professor, Pediatrics, USC School of Medicine

Join to view full profile

Dr. Gaynon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gaynon's full profile

Already have an account?

Office
4650 W Sunset Blvd
Los Angeles, CA 90027
Phone+1 323-361-2163

Fax+1 323-361-7128

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 1974 - 1976
University of Illinois College of MedicineClass of 1974
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology

Certifications & Licensure

CA State Medical License 1998 - 2026
WI State Medical License 1987 - 1999
IL State Medical License 1976 - 1990
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia Start of enrollment: 2002 Nov 01
Completed
Phase 2
ABT-751 With Chemotherapy for Relapsed Pediatric ALL Start of enrollment: 2006 May 22
Terminated
Phase 1, Phase 2
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) Start of enrollment: 2009 Apr 13
Terminated
Phase 1
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) Start of enrollment: 2009 Jul 10
Terminated
Phase 2
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL Start of enrollment: 2010 Jun 01
Terminated
Phase 1, Phase 2
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Start of enrollment: 2011 Mar 01
Completed
Phase 1
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Start of enrollment: 2011 Dec 01
Terminated
Phase 1, Phase 2
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Start of enrollment: 2014 May 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Clinical Relapse Versus Treatment Failure: The Case for Surveillance for Re-Appearance of Minimal Measurable Disease in Pediatric Patients with Higher Risk B-ALL.
Paul S Gaynon, Linwei Li
Pediatric Blood & Cancer. 2025-01-01
Development of second genetically distinct T-lymphoblastic leukemia in a pediatric patient.
Haley Hultquist, Alyssa Rodriguez, Juanita E Ferreira, Juanita E Ferreira, Alexandra Placek
Pediatric Blood & Cancer. 2024-08-01
Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
Andrew Doan, Holly K T Huang, Ari J Hadar, Jemily Malvar, Teresa Rushing
British Journal of Haematology. 2023-07-01

Grant Support

Clinical Trial: ABT-751 Combined With Dexamethasone, Peg-Asparaginase, And DoxorNational Center For Research Resources2009
Childrens Cancer GroupNational Cancer Institute1998–2002
Childrens Cancer GroupNational Cancer Institute1997
Childrens CancerNational Cancer Institute1994–1996
Children'S Cancer Study GroupNational Cancer Institute1989–1993